Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma
Amicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease and is driving consistent revenue growth. Key growth drivers for Galafold include expanding patient reach, new markets, increased market share, and high patient adherence.
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - President & Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Joshua Fleishman - TD Cowen Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Gil Blum - Needham & Company Operator Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics First Quarter 2025 Financial Results Conference Call and Webcast. At this time, participants are in a listen-only mode.
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)
Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving revenue, with significant market share and potential label expansions, targeting $1bn revenue by 2028. The company has a solid financial position, minimal near-term competition, and a favorable patent settlement with Teva, ensuring market exclusivity until 2037.
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Kristen Kluska - Cantor Fitzgerald Malcolm Kuno - JPMorgan Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Jeff Hung - Morgan Stanley Joshua Fleishman - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Full Year 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago.
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
